Joseph Catanzaro

Andy Hsieh

Marc Frahm

Tsan-Yu Hsieh

Andy Shah

Gum-Ming Lowe

Robert Burns

- Cardiff Oncology's lead asset, **onvansertib**, is an oral small molecule targeting PLK1, being developed for **first-line RAS-mutated metastatic colorectal cancer**.  **[0001213037_2174292_0]** **[0001213037_2174292_1]** 
- The Phase II CARDIFF-004 trial, as updated in July 2025, demonstrated a **confirmed objective response rate of 49%**, representing a nearly **20% improvement over control**.  **[0001213037_2174292_1]** 
- The company reported **$71 million in cash and investments as of June 30, 2025**, which is projected to fund operations into **early 2027**.  **[0001213037_2174292_5]** 
- A key upcoming catalyst is the **next update from the CARDIFF-004 trial in Q1 2026**, expected to provide more informative data on durability measures such as progression-free survival.  **[0001213037_2174292_5]** **[0001213037_2174292_6]** 
- Analysts estimate peak sales for onvansertib to be between **$2 billion and $3 billion annually**, with the company identifying an open competitive field in first-line RAS-mutated MCRC.  **[0001213037_2174292_7]**

Cardiff Oncology (CRDF)